Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3558
Gene Symbol: IL2
IL2
0.010 Biomarker phenotype BEFREE Interleukin-2 was elevated after gluten in 97% of patients (median fold-change: 20), and correlated with severity of nausea (r<sub>s</sub>  = .49, P = .0025) and occurrence of vomiting (P = .0005). 31769533 2020
Entrez Id: 2185
Gene Symbol: PTK2B
PTK2B
0.010 Biomarker phenotype BEFREE Based upon our preliminary findings, we postulated Akt's involvement in emesis. 31738972 2020
Entrez Id: 207
Gene Symbol: AKT1
AKT1
0.010 Biomarker phenotype BEFREE Based upon our preliminary findings, we postulated Akt's involvement in emesis. 31738972 2020
Entrez Id: 112476
Gene Symbol: PRRT2
PRRT2
0.010 Biomarker phenotype BEFREE Furthermore, our behavioral findings demonstrated that the following agents suppressed vomiting evoked by GR73632 in a dose-dependent manner: i) the NK<sub>1</sub>R antagonist netupitant (i.p.); ii) the L-type Ca<sup>2+</sup> channel (LTCC) antagonist nifedipine (subcutaneous, s.c.); iii) the inositol trisphosphate receptor (IP<sub>3</sub>R) antagonist 2-APB (i.p.); iv) store-operated Ca<sup>2+</sup> entry inhibitors YM-58483 and MRS-1845, (i.p.); v) the ERK1/2 pathway inhibitor U0126 (i.p.); vi) the PKC inhibitor GF109203X (i.p.); and vii) the inhibitor of phosphatidylinositol 3-kinase (PI3K)-Akt pathway LY294002 (i.p.). 30453005 2019
Entrez Id: 28982
Gene Symbol: FLVCR1
FLVCR1
0.010 GeneticVariation phenotype BEFREE In group RD, cumulative morphine dose and numbers of PCA analgesia in group RD were significantly reduced, the time of first analgesic demand was significantly delayed compared to the group R. Visual Analog Scale in group RD showed a marked reduction at 8 hours, 12 hours, 16 hours after operation and less patients in group RD experienced postoperative nausea or vomiting compared to the group R. 31095117 2019
Entrez Id: 5578
Gene Symbol: PRKCA
PRKCA
0.010 Biomarker phenotype BEFREE Furthermore, our behavioral findings demonstrated that the following agents suppressed vomiting evoked by GR73632 in a dose-dependent manner: i) the NK<sub>1</sub>R antagonist netupitant (i.p.); ii) the L-type Ca<sup>2+</sup> channel (LTCC) antagonist nifedipine (subcutaneous, s.c.); iii) the inositol trisphosphate receptor (IP<sub>3</sub>R) antagonist 2-APB (i.p.); iv) store-operated Ca<sup>2+</sup> entry inhibitors YM-58483 and MRS-1845, (i.p.); v) the ERK1/2 pathway inhibitor U0126 (i.p.); vi) the PKC inhibitor GF109203X (i.p.); and vii) the inhibitor of phosphatidylinositol 3-kinase (PI3K)-Akt pathway LY294002 (i.p.). 30453005 2019
Entrez Id: 5579
Gene Symbol: PRKCB
PRKCB
0.010 Biomarker phenotype BEFREE Furthermore, our behavioral findings demonstrated that the following agents suppressed vomiting evoked by GR73632 in a dose-dependent manner: i) the NK<sub>1</sub>R antagonist netupitant (i.p.); ii) the L-type Ca<sup>2+</sup> channel (LTCC) antagonist nifedipine (subcutaneous, s.c.); iii) the inositol trisphosphate receptor (IP<sub>3</sub>R) antagonist 2-APB (i.p.); iv) store-operated Ca<sup>2+</sup> entry inhibitors YM-58483 and MRS-1845, (i.p.); v) the ERK1/2 pathway inhibitor U0126 (i.p.); vi) the PKC inhibitor GF109203X (i.p.); and vii) the inhibitor of phosphatidylinositol 3-kinase (PI3K)-Akt pathway LY294002 (i.p.). 30453005 2019
Entrez Id: 11169
Gene Symbol: WDHD1
WDHD1
0.010 Biomarker phenotype BEFREE Dehydrated children aged 6 to 60 months with ≥1 diarrheal (ie, loose or liquid) stool and ≥1 vomiting episode within the preceding 4 hours were eligible to participate. 31694979 2019
Entrez Id: 7357
Gene Symbol: UGCG
UGCG
0.010 Biomarker phenotype BEFREE Univariate and multivariate analyses revealed that pupillary asymmetry, pyramidal signs, low GCS at presentation, associated parenchymal injuries, and post-operative complications correlated negatively with outcome, whereas vomiting correlated positively with outcome. 30796557 2019
Entrez Id: 5291
Gene Symbol: PIK3CB
PIK3CB
0.010 Biomarker phenotype BEFREE Furthermore, our behavioral findings demonstrated that the following agents suppressed vomiting evoked by GR73632 in a dose-dependent manner: i) the NK<sub>1</sub>R antagonist netupitant (i.p.); ii) the L-type Ca<sup>2+</sup> channel (LTCC) antagonist nifedipine (subcutaneous, s.c.); iii) the inositol trisphosphate receptor (IP<sub>3</sub>R) antagonist 2-APB (i.p.); iv) store-operated Ca<sup>2+</sup> entry inhibitors YM-58483 and MRS-1845, (i.p.); v) the ERK1/2 pathway inhibitor U0126 (i.p.); vi) the PKC inhibitor GF109203X (i.p.); and vii) the inhibitor of phosphatidylinositol 3-kinase (PI3K)-Akt pathway LY294002 (i.p.). 30453005 2019
Entrez Id: 847
Gene Symbol: CAT
CAT
0.010 AlteredExpression phenotype BEFREE A significant decrease (p < 0.01) of CAT activity was observed in the extract (200 mg/kg) group in emesis induced by copper sulfate in chickens brain mitochondria. 29250976 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.010 Biomarker phenotype BEFREE Furthermore, our behavioral findings demonstrated that the following agents suppressed vomiting evoked by GR73632 in a dose-dependent manner: i) the NK<sub>1</sub>R antagonist netupitant (i.p.); ii) the L-type Ca<sup>2+</sup> channel (LTCC) antagonist nifedipine (subcutaneous, s.c.); iii) the inositol trisphosphate receptor (IP<sub>3</sub>R) antagonist 2-APB (i.p.); iv) store-operated Ca<sup>2+</sup> entry inhibitors YM-58483 and MRS-1845, (i.p.); v) the ERK1/2 pathway inhibitor U0126 (i.p.); vi) the PKC inhibitor GF109203X (i.p.); and vii) the inhibitor of phosphatidylinositol 3-kinase (PI3K)-Akt pathway LY294002 (i.p.). 30453005 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.010 Biomarker phenotype BEFREE Furthermore, our behavioral findings demonstrated that the following agents suppressed vomiting evoked by GR73632 in a dose-dependent manner: i) the NK<sub>1</sub>R antagonist netupitant (i.p.); ii) the L-type Ca<sup>2+</sup> channel (LTCC) antagonist nifedipine (subcutaneous, s.c.); iii) the inositol trisphosphate receptor (IP<sub>3</sub>R) antagonist 2-APB (i.p.); iv) store-operated Ca<sup>2+</sup> entry inhibitors YM-58483 and MRS-1845, (i.p.); v) the ERK1/2 pathway inhibitor U0126 (i.p.); vi) the PKC inhibitor GF109203X (i.p.); and vii) the inhibitor of phosphatidylinositol 3-kinase (PI3K)-Akt pathway LY294002 (i.p.). 30453005 2019
Entrez Id: 6581
Gene Symbol: SLC22A3
SLC22A3
0.010 Biomarker phenotype BEFREE Kaplan-Meier analysis revealed that the adjusted hazard ratio of successful intubation for post-training versus pre-training scenario was 2.13 (95% confidence interval of 1.57-2.91).The S.A.L.A.D. technique training could efficiently help EMT-P performing endotracheal intubation during massive vomiting simulation. 31725637 2019
Entrez Id: 2729
Gene Symbol: GCLC
GCLC
0.010 Biomarker phenotype BEFREE Univariate and multivariate analyses revealed that pupillary asymmetry, pyramidal signs, low GCS at presentation, associated parenchymal injuries, and post-operative complications correlated negatively with outcome, whereas vomiting correlated positively with outcome. 30796557 2019
Entrez Id: 213
Gene Symbol: ALB
ALB
0.010 Biomarker phenotype BEFREE Predictive factors for toxicities were as follows: higher risk stratification and higher values of albumin (ALB) for leucopenia, higher values of white blood cell count (WBC) for anemia, higher values of ALB and creatinine (Cr) for neutropenia, higher risk stratification and higher 44-h MTX concentration for febrile neutropenia, higher values of alanine transferase (ALT) for elevated ALT, higher values of ALT for elevated aspartate transferase (AST), and higher values of total bilirubin (TBil) for vomiting. 31308758 2019
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
0.010 Biomarker phenotype BEFREE Furthermore, our behavioral findings demonstrated that the following agents suppressed vomiting evoked by GR73632 in a dose-dependent manner: i) the NK<sub>1</sub>R antagonist netupitant (i.p.); ii) the L-type Ca<sup>2+</sup> channel (LTCC) antagonist nifedipine (subcutaneous, s.c.); iii) the inositol trisphosphate receptor (IP<sub>3</sub>R) antagonist 2-APB (i.p.); iv) store-operated Ca<sup>2+</sup> entry inhibitors YM-58483 and MRS-1845, (i.p.); v) the ERK1/2 pathway inhibitor U0126 (i.p.); vi) the PKC inhibitor GF109203X (i.p.); and vii) the inhibitor of phosphatidylinositol 3-kinase (PI3K)-Akt pathway LY294002 (i.p.). 30453005 2019
Entrez Id: 6051
Gene Symbol: RNPEP
RNPEP
0.010 Biomarker phenotype BEFREE Furthermore, our behavioral findings demonstrated that the following agents suppressed vomiting evoked by GR73632 in a dose-dependent manner: i) the NK<sub>1</sub>R antagonist netupitant (i.p.); ii) the L-type Ca<sup>2+</sup> channel (LTCC) antagonist nifedipine (subcutaneous, s.c.); iii) the inositol trisphosphate receptor (IP<sub>3</sub>R) antagonist 2-APB (i.p.); iv) store-operated Ca<sup>2+</sup> entry inhibitors YM-58483 and MRS-1845, (i.p.); v) the ERK1/2 pathway inhibitor U0126 (i.p.); vi) the PKC inhibitor GF109203X (i.p.); and vii) the inhibitor of phosphatidylinositol 3-kinase (PI3K)-Akt pathway LY294002 (i.p.). 30453005 2019
Entrez Id: 183
Gene Symbol: AGT
AGT
0.010 Biomarker phenotype BEFREE In addition to its function as vomiting center, several others are part of the circumventricular organs for vasomotor/angiotensin II regulation, role in neuromyelitis optica related to aquaporin-4, and somatic growth and appetite regulation.Functions are immature at birth. 30797593 2019
Entrez Id: 4763
Gene Symbol: NF1
NF1
0.010 Biomarker phenotype BEFREE A 22-year-old male with neurofibromatosis-1 presented with sudden onset headache and vomiting of 3-day duration. 28980149 2019
Entrez Id: 3702
Gene Symbol: ITK
ITK
0.010 Biomarker phenotype BEFREE Kaplan-Meier analysis revealed that the adjusted hazard ratio of successful intubation for post-training versus pre-training scenario was 2.13 (95% confidence interval of 1.57-2.91).The S.A.L.A.D. technique training could efficiently help EMT-P performing endotracheal intubation during massive vomiting simulation. 31725637 2019
Entrez Id: 4149
Gene Symbol: MAX
MAX
0.010 Biomarker phenotype BEFREE The BD-MAX™ System with user defined settings and the Xpert® Norovirus Assay showed acceptable sensitivity and specificity for detection of norovirus from stool and vomit. 29908520 2018
Entrez Id: 5142
Gene Symbol: PDE4B
PDE4B
0.010 Biomarker phenotype BEFREE These novel findings confirm a major role for PDE4B in skeletal muscle proteolysis in burn injury and suggest that an innovative therapy based on PDE4B-selective inhibitors could be developed to treat skeletal muscle cachexia in burn injury without the fear of causing emesis, which is associated with PDE4D inhibition. 29693432 2018
Entrez Id: 3257
Gene Symbol: HPS1
HPS1
0.010 Biomarker phenotype BEFREE Vomiting duration at presentation in HPS does not seem to have a significant impact on postoperative outcomes. 29411105 2018
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.010 Biomarker phenotype BEFREE Intense FDG Uptake in the Muscles Due to Severe Vomiting. 30004938 2018